164 - Management of Respiratory Viruses in Transplant Recipients in the Post-COVID-19 Pandemic Era

Tuesday, October 21, 2025

1:45 PM - 3:00 PM US ET

Location: Thomas B. Murphy Ballroom 4

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Joanna Schaenman, MD, PhD, FAST (she/her/hers)

Professor, Department of Medicine, Division of Infectious Diseases
University of California Los Angeles, David Geffen School of Medicine
Los Angeles, CA, United States
Deepali Kumar, MD, MSc, FRCPC

Professor of Medicine
University Of Toronto
Toronto, ON, Canada

Faculty(s)

Lara Danziger-Isakov, MD, MPH

Professor
Infectious Disease
Cincinnati Children's Hospital
Cincinnati, OH, United States
Roy Chemaly, MD/MPH (he/him/his)

Gerald P Bodey, Sr Distinguished Professor of Infectious Diseases
Infectious Diseases
University of Texas MD Anderson Cancer Center
Houston, TX, United States

Disclosure(s):

Joanna M. Schaenman, MD, PhD, FAST: Merck and Company, Inc.: Grant/Research Support

Deepali Kumar, MD, MSc, FRCPC: Eurofins Viracor: Honoraria; GSK: Advisor/Consultant, Grant/Research Support; Merck and Company, Inc.: Advisor/Consultant; Moderna, Inc.: Grant/Research Support; Paladin Labs: Honoraria; Takeda Canada: Advisor/Consultant, Grant/Research Support

Lara A. Danziger-Isakov, MD, MPH: AiCuris.: Grant/Research Support; Ansun BioPharma: Grant/Research Support; Astellas Pharma Global Development, Inc: Advisor/Consultant, Grant/Research Support; kamada: Advisor/Consultant; Merck Sharp & Dohme Corporation: Grant/Research Support; Pfizer (Any division): Grant/Research Support; Takeda Pharmaceuticals: Grant/Research Support

Roy F. Chemaly, MD/MPH: ADMA Biologics, Inc.: Advisor/Consultant; AiCuris Anti-Infective Cures AG: Advisor/Consultant, Grant/Research Support; Ansun Biopharma Inc.: Advisor/Consultant, Grant/Research Support; Assembly Bioscience: Advisor/Consultant; Astellas Pharma Inc.: Advisor/Consultant; Eurofins-Viracor: Advisor/Consultant, Grant/Research Support, Honoraria; Gilead Biosciences: Advisor/Consultant; Invivyd, Inc.: Advisor/Consultant; Karius Inc.: Advisor/Consultant, Grant/Research Support; Merck and Company, Inc.: Advisor/Consultant, Grant/Research Support, Honoraria; Moderna, Inc.: Advisor/Consultant; Pfizer Pharmaceutc: Advisor/Consultant; Roche/Genentech: Grant/Research Support; SHIONOGI and CO., LTD.: Advisor/Consultant; Takeda Pharmaceutical: Advisor/Consultant, Grant/Research Support; Tether: Advisor/Consultant

Learning Objectives:

At the conclusion of this session, participants will be able to:

explain how respiratory viruses uniquely impact immunocompromised patients and what areas of opportunity exist to improve treatment and prevention;
discuss options for antiviral and other treatment approaches for the immunocompromised patient with acute or persistent infection;
describe the current landscape for clinical trials for antivirals to limit impact of respiratory virus infection on immunocompromised hosts.

Presentations:

1:45 PM - 2:10 PM US ET

Burden of Respiratory Viruses in Immunocompromised Hosts (ICHs): Gaps and Opportunities in Treatment
Speaker: Lara A. Danziger-Isakov, MD, MPH – Cincinnati Children's Hospital
2:10 PM - 2:35 PM US ET

Management of Acute and/or Persistent Viral Respiratory Tract Infections in Immunocompromised Hosts
Speaker: Deepali Kumar, MD, MSc, FRCPC – University Of Toronto
2:35 PM - 3:00 PM US ET

Outlook in Clinical Trials in Antivirals for Respiratory Viruses: Lessons Learned Over the Years
Speaker: Roy F. Chemaly, MD/MPH (he/him/his) – University of Texas MD Anderson Cancer Center